LLY250103P500000
- 0.00
- 0.000.00%
Eli Lilly and Co Newsroom
Express News | Orbis Medicines: Financing Led by Nea With Participation From Eli Lilly, Export and Investment Fund of Denmark, Novo Holdings, Forbion, Others
Israel Englander's Millennium Management Dumps Nvidia, Loads Up On Broadcom — Here's What The $70 Billion Hedge Fund Sees
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50
Novo Nordisk Seeks to Block Compounded Victoza
Smart Money Is Betting Big In LLY Options
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
Express News | Eli Lilly and Co seeks to intervene in the lawsuit between the USA Food and Drug Administration (FDA) and numerous pharmacists regarding whether there is still a supply shortage of Eli Lilly's weight-loss drug Tirzepatide. Eli Lilly claims that all of its
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
The three major US stock index futures rose collectively, and all seven giants were up in pre-market trading | Highlights for tonight.
① NVIDIA GB300 may be released in the second quarter of 2025; ② Eli Lilly and Co's weight loss drug tirzepatide has officially launched in China; ③ Apple announces price reductions.
U.S. stock forecast | The three major futures indices surged collectively, Growth Tech and quantum computing stocks rose before the market opens; the retail investor "leader" has made another move! Unity skyrocketed over 13% before the market.
South Korean retail investors are shifting to the U.S. stock market, with Tesla being the biggest winner; Apple is reducing prices! Save up to 800 yuan; a well-known bull on Wall Street sounds the alarm: U.S. stocks may see a correction of 10%-15% in the first half of the year.
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Pre-Market Trading Highlights | Nasdaq Futures rise over 1.2% as Goldman Sachs expects the Federal Reserve to cut rates by 75 basis points this year.
Gelonghui, January 2 | 1. The three major Equity Index futures in the USA all rose, with Nasdaq futures up by 1.27%, S&P 500 Index futures up by 1.07%, and Dow futures up by 0.85%.